Search results for "FUNGAL"

showing 10 items of 1116 documents

Portal Vein Thrombosis in a Preterm Newborn with Mutation of the MTHFR and PAI-1 Genes and Sepsis by Candida parapsilosis

2016

Objective This report discusses the role of both congenital and acquired risk factors in the pathogenesis of portal vein thrombosis (PVT). Study Design We describe the clinical management and treatment of PVT in a preterm newborn with a homozygous mutation of the methylenetetrahydrofolate reductase (MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes and sepsis by Candida parapsilosis. Results Although literature data suggest a minor role of genetic factors in thrombophilia in the case of only one mutation, we hypothesize that combined thrombophilic genetic defects may have a cumulative effect and significantly increase the thrombotic risk. Conclusion It could be appropriate to incl…

MalePathologymedicine.medical_specialtyCandida parapsilosis030204 cardiovascular system & hematologyBioinformaticsCandida parapsilosisThrombophiliaSepsisPathogenesis03 medical and health sciences0302 clinical medicineSepsis030225 pediatricsPlasminogen Activator Inhibitor 1medicineHumansMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisPolymorphism GeneticbiologyPortal Veinbusiness.industryCandidiasisInfant NewbornAnticoagulantsFactor VObstetrics and Gynecologyportal thrombosis fungal infection gene polymorphismmedicine.diseasebiology.organism_classificationPortal vein thrombosisSurgical Procedures OperativeMethylenetetrahydrofolate reductaseMutationPediatrics Perinatology and Child Healthbiology.proteinGene polymorphismbusinessPlasminogen activatorAmerican Journal of Perinatology
researchProduct

A case of Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis.

2011

A case of a 62-year-old man with Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis that was successfully treated with a 14-day course of caspofungin is reported. The potential role of Candida infection in the pathogenesis of peptic ulcers and duodenal perforation is considered. If this role is confirmed, antifungal treatment should be included in the therapeutic armamentarium of peptic disease.

MalePeptic Ulcermedicine.medical_specialtyAntifungal AgentsVeterinary (miscellaneous)PepticPeritonitisPeritonitisApplied Microbiology and BiotechnologyMicrobiologyGastroenterologyPathogenesisEchinocandinsLipopeptideschemistry.chemical_compoundMedical microbiologyDuodenitisCaspofunginInternal medicineCandida kruseimedicineHumansDuodenal DiseasesDuodenal PerforationPeptic diseaseCandidaDuodenal perforationDuodenitibiologyPeritonitibusiness.industrySmokingCandidiasisCandida Peritonitis Duodenal perforation Duodenitis Peptic disease Caspofungin SmokingMiddle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesTreatment OutcomechemistryIntestinal PerforationCaspofunginbusinessAgronomy and Crop Science
researchProduct

Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole

2008

ABSTRACT We investigated the in vitro activities of posaconazole (POS), fluconazole (FLC), amphotericin B (AMB), and caspofungin (CAS) against four clinical isolates of Candida glabrata with various susceptibilities to FLC (FLC MICs ranging from 1.0 to >64 μg/ml). POS MICs ranged from ≤0.03 to 0.5 μg/ml; AMB MICs ranged from 0.25 to 2.0 μg/ml, while CAS MICs ranged from 0.03 to 0.25 μg/ml. When FLC MICs increased, so did POS MICs, although we did not observe any isolate with a POS MIC greater than 0.5 μg/ml. Time-kill experiments showed that POS, FLC, and CAS were fungistatic against all isolates, while AMB at eight times the MIC was fungicidal against three out of four isolates of C. gl…

MalePosaconazoleAntifungal AgentsCandida glabrataMicrobial Sensitivity TestsDrug resistanceBiologyKidneyMicrobiologyMicechemistry.chemical_compoundDrug Resistance Fungalhemic and lymphatic diseasesAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)FluconazolePharmacologyCandida glabrataExperimental modelCandidiasisFungi imperfectiTriazolesbiology.organism_classificationTreatment OutcomeInfectious DiseaseschemistryCaspofunginFluconazolemedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

A comparative study on cell wall antigens and cell surface hydrophobicity in clinical isolates ofCandida albicans

1994

Characterization of common cell surface-bound antigens in Candida albicans strains, particularly those expressed in the walls of mycelial cells might be useful in the diagnosis of systemic candidiasis. Hence, antigenic similarities among wall proteins and mannoproteins from C. albicans clinical serotype A and B isolates, were studied using polyclonal (mPAbs) and monoclonal (MAb 4C12) antibodies raised against wall antigens from the mycelial form of a common C. albicans serotype A laboratory strain (ATCC 26555). Zymolyase digestion of walls isolated from cells of the different strains studied grown at 37 degrees C (germination conditions), released, in all cases, numerous protein and mannopr…

MaleSerotypeAntigens FungalVeterinary (miscellaneous)Blotting WesternPopulationApplied Microbiology and BiotechnologyMicrobiologyAntibodiesMicrobiologyCell wallAntigenCell WallCandida albicansmedicineAnimalsHumansCandida albicanseducationeducation.field_of_studybiologyCandidiasisbiology.organism_classificationmedicine.diseaseCorpus albicansPolyclonal antibodiesAntigens Surfacebiology.proteinElectrophoresis Polyacrylamide GelFemaleRabbitsSystemic candidiasisAgronomy and Crop ScienceMycopathologia
researchProduct

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B

2008

ABSTRACT We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed by posaconazole (POS) against Candida glabrata . The susceptibilities to POS of yeast cells pre-exposed to CAS or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequential regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but this treatment was not superior to the use of …

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaPosaconazoleAntifungal Agentsmedicine.drug_classAntibioticsColony Count MicrobialCandida glabrataMicrobial Sensitivity TestsBiologyPharmacologyKidneyDrug Administration ScheduleMicrobiologyEchinocandinsLipopeptidesMicechemistry.chemical_compoundCaspofunginAmphotericin BAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)Viability assayPharmacologyCandida glabrataPosaconazole Candida glabrataCandidiasisTriazolesbacterial infections and mycosesbiology.organism_classificationDisseminated CandidiasisRegimenTreatment OutcomeInfectious DiseaseschemistryCaspofunginmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Phase II dose escalation study of caspofungin for invasive Aspergillosis.

2011

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥4 in 2 of 8 patients or ≥3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics w…

Malemedicine.medical_specialtyAntifungal AgentsDoseBiologyPharmacologyClinical TherapeuticsAspergillosisGastroenterologyDrug Administration ScheduleCohort Studieschemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginInternal medicinemedicineAspergillosisHumansPharmacology (medical)PharmacologyVoriconazoleVolume of distributionDose-Response Relationship DrugLiterMiddle Agedmedicine.diseaseSurvival AnalysisInfectious DiseasesTreatment OutcomechemistryToxicityFemaleCaspofunginmedicine.drugFollow-Up StudiesAntimicrobial agents and chemotherapy
researchProduct

A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children

2012

Given that the rationale for empirical antifungal therapy in neutropenic children is limited and based on adult patient data, we performed a prospective, randomized, controlled trial that evaluated 110 neutropenic children with persistent fever. Those at high risk for invasive fungal infections (IFI) received caspofungin (Arm C) or liposomal amphotericinB (Arm B); those with a lower risk were randomized to receive Arm B, C, or no antifungal treatment (Arm A). Complete response to empirical antifungal therapy was achieved in 90/104 patients (86·5%): 48/56 at high risk (85·7%) [88·0% in Arm B; 83·9% in Arm C (P = 0·72)], and 42/48 at low risk (87·5%) [87·5% in control Arm A, 80·0% Arm B, 94·1…

Malemedicine.medical_specialtyAntifungal AgentsNeutropeniaAntineoplastic AgentsOpportunistic InfectionsLower riskFever of Unknown Originlaw.inventionEchinocandinsLipopeptideschemistry.chemical_compoundRandomized controlled trialCaspofunginlawAmphotericin BInternal medicinemedicineHumansProspective StudiesChildProspective cohort studyempirical antifungal therapy children cancerbusiness.industryPatient SelectionInfantCancerHematologyLength of Staymedicine.diseaseConfidence intervalSurgeryHospitalizationTreatment OutcomeMycoseschemistryChild PreschoolFemaleCaspofunginbusinessEmpiric therapyFebrile neutropeniaBritish Journal of Haematology
researchProduct

Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study

2015

Background: Invasive candidiasis (IC) is a frequent and life-threatening infection in critically ill patients. The aim of this study was to evaluate the epidemiology of IC and the antifungal susceptibility of etiological agents in patients admitted to our surgical intensive care unit (SICU) in Spain. Methods: We designed a prospective, observational, single center, population-based study in a SICU. We included all consecutive adult patients (≥18 years old) who had documented IC, either on admission or during their stay, between January 2012 and December 2013. Results: There were a total of 22 episodes of IC in the 1149 patients admitted during the 24-month study. The overall IC incidence wa…

Malemedicine.medical_specialtyAntifungal AgentsPopulationMicrobiologiaMicrobial Sensitivity TestsCandida parapsilosisGeneral Biochemistry Genetics and Molecular Biologylaw.inventionCandida tropicalisDrug Resistance FungallawInternal medicineCandida kruseiAbdomenmedicineHumansSurgical Wound InfectionIntensive care unitCandidiasis InvasiveCandida albicanseducationEpidemiologiaAgedCandidaMedicine(all)education.field_of_studyCandida glabratabiologybusiness.industryBiochemistry Genetics and Molecular Biology(all)CandidemiaGeneral MedicineFongs patògensMiddle Agedbiology.organism_classificationIntensive care unitSurgeryInvasive candidiasisIntensive Care UnitsTreatment OutcomeSpainFemalebusinessAntifungal susceptibilitySurgery Department HospitalFluconazoleResearch Articlemedicine.drugBMC Research Notes
researchProduct

Chronic hyperplastic candidosis: a pilot study of the efficacy of 0.18% isotretinoin.

2009

Management of oral candidiasis depends on an accurate diagnosis, identification and elimination of predisposing factors, and, often, use of antifungal agents. Chronic hyperplastic candidosis (CHC) is considered a premalignant lesion of the oral mucosa, occurring as speckled or homogeneous white lesions. If the lesions are untreated, a minor proportion may become dysplastic and progress to carcinoma. The traditional treatment of this lesion is based on the use of antifungal agents. The aim of this study was to examine the efficacy of 0.18% isotretinoin for treatment of nystatin-resistant candidiasis. Isotretinoin was administered topically twice a day for one month to six patients affected b…

Malemedicine.medical_specialtyNystatinAntifungal AgentsAdministration TopicalPilot ProjectsLesionSettore MED/28 - Malattie OdontostomatologicheCandidiasis OralDrug Resistance FungalSicca syndromeOral and maxillofacial pathologymedicineCarcinomaHumansOral mucosaIsotretinoinGeneral DentistryStomatitisIsotretinoinbusiness.industryMiddle Agedmedicine.diseaseDermatologySurgeryNystatinmedicine.anatomical_structureChronic DiseaseChronic hyperplastic candidosisFemalemedicine.symptombusinessmedicine.drugJournal of oral science
researchProduct

Langerin+ DCs regulate innate IL-17 production in the oral mucosa during Candida albicans-mediated infection

2018

The opportunistic fungal pathogen Candida albicans frequently causes diseases such as oropharyngeal candidiasis (OPC) in immunocompromised individuals. Although it is well appreciated that the cytokine IL-17 is crucial for protective immunity against OPC, the cellular source and the regulation of this cytokine during infection are still a matter of debate. Here, we directly visualized IL-17 production in the tongue of experimentally infected mice, thereby demonstrating that this key cytokine is expressed by three complementary subsets of CD90+ leukocytes: RAG-dependent αβ and γδ T cells, as well as RAG-independent ILCs. To determine the regulation of IL-17 production at the onset of OPC, we…

Malemedicine.medical_treatment2405 ParasitologyPathology and Laboratory Medicine10263 Institute of Experimental ImmunologyMonocytesMice0302 clinical medicineAnimal CellsCandida albicansBiology (General)Candida albicansMononuclear Phagocyte SystemFungal PathogensInnate Immune Systemeducation.field_of_studyEukaryotaMononuclear phagocyte systemFlow CytometryCorpus albicans3. Good healthSpectrophotometryMedical MicrobiologyCytokinesCytophotometryCellular Types10244 Institute of VirologyQH301-705.5Immune CellsImmunologyMicrobiology03 medical and health sciences1311 GeneticsGenetics1312 Molecular BiologyeducationMicrobial PathogensMolecular BiologyMouth2403 ImmunologyBlood CellsOrganismsBiology and Life SciencesDendritic CellsMolecular DevelopmentYeastMice Inbred C57BLMannose-Binding Lectins030104 developmental biologyImmunologyThy-1 Antigens570 Life sciences; biologyParasitologyImmunologic diseases. AllergyDigestive SystemDevelopmental Biology0301 basic medicineNeutrophilsPhysiologyInterleukin-1betaYeast and Fungal ModelsInterleukin-23White Blood CellsSpectrum Analysis TechniquesCandidiasis OralImmune PhysiologyLeukocytesMedicine and Health SciencesCandidaStainingbiologyInterleukin-172404 MicrobiologyCell StainingSpecific Pathogen-Free OrganismsInfectious DiseasesCytokineExperimental Organism SystemsAntigens SurfaceFemaleAnatomyPathogensResearch ArticleLangerinPopulationMycologyOpportunistic InfectionsResearch and Analysis MethodsTongueImmunityVirologymedicineAnimalsLectins C-TypeInterleukin 6Interleukin-6Mouth MucosaFungiCell BiologyRC581-607biology.organism_classificationSpecimen Preparation and TreatmentImmune Systembiology.protein2406 VirologySpleen030215 immunology
researchProduct